IJMS

#IJMS | 来源: 网络整理| 查看: 265

Next Article in Journal Unveiling New Druggable Pockets in Influenza Non-Structural Protein 1: NS1–Host Interactions as Antiviral Targets for Flu Previous Article in Journal Prevalence and Mechanisms of Skeletal Muscle Atrophy in Metabolic Conditions Previous Article in Special Issue Using a Network-Based Analysis Approach to Investigate the Involvement of S. aureus in the Pathogenesis of Granulomatosis with Polyangiitis Journals Active Journals Find a Journal Proceedings Series Topics Information For Authors For Reviewers For Editors For Librarians For Publishers For Societies For Conference Organizers Open Access Policy Institutional Open Access Program Special Issues Guidelines Editorial Process Research and Publication Ethics Article Processing Charges Awards Testimonials Author Services Initiatives Sciforum MDPI Books Preprints Scilit SciProfiles Encyclopedia JAMS Proceedings Series About Overview Contact Careers News Blog Sign In / Sign Up Notice clear Notice

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.

Continue Cancel clear

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Feature Papers represent the most advanced research with significant potential for high impact in the field. Feature Papers are submitted upon individual invitation or recommendation by the scientific editors and undergo peer review prior to publication.

The Feature Paper can be either an original research article, a substantial novel research study that often involves several techniques or approaches, or a comprehensive review paper with concise and precise updates on the latest progress in the field that systematically reviews the most exciting advances in scientific literature. This type of paper provides an outlook on future directions of research or possible applications.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Journals Active Journals Find a Journal Proceedings Series Topics Information For Authors For Reviewers For Editors For Librarians For Publishers For Societies For Conference Organizers Open Access Policy Institutional Open Access Program Special Issues Guidelines Editorial Process Research and Publication Ethics Article Processing Charges Awards Testimonials Author Services Initiatives Sciforum MDPI Books Preprints Scilit SciProfiles Encyclopedia JAMS Proceedings Series About Overview Contact Careers News Blog Sign In / Sign Up Submit Journals IJMS Volume 24 Issue 3 10.3390/ijms24032975

Submit to this Journal Review for this Journal Edit a Special Issue ► ▼ Article Menu Article Menu Academic Editor

Kim M. O’Sullivan Subscribe SciFeed Related Info Link Google Scholar More by Authors Links on DOAJ Hakroush, S. Tampe, B. on Google Scholar Hakroush, S. Tampe, B. on PubMed Hakroush, S. Tampe, B. /ajax/scifeed/subscribe Article Views Citations - Table of Contents Altmetric share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up ... Endorse textsms ... Comment Need Help? Support

Find support for a specific problem in the support section of our website.

Get Support Feedback

Please let us know what you think of our products and services.

Give Feedback Information

Visit our dedicated information section to learn more about MDPI.

Get Information clear JSmol Viewer clear first_page settings Order Article Reprints Font Type: Arial Georgia Verdana Font Size: Aa Aa Aa Line Spacing:    Column Width:    Background: Open AccessCommunication Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis by

Samy Hakroush 1,2 ORCID

and

Björn Tampe 3,* ORCID

1 Institute of Pathology, University Medical Center Göttingen, 37075 Göttingen, Germany 2 SYNLAB Pathology Hannover, SYNLAB Holding Germany, 86156 Augsburg, Germany 3 Department of Nephrology and Rheumatology, University Medical Center Göttingen, 37075 Göttingen, Germany * Author to whom correspondence should be addressed. Int. J. Mol. Sci. 2023, 24(3), 2975; https://doi.org/10.3390/ijms24032975 Received: 5 December 2022 / Revised: 18 January 2023 / Accepted: 31 January 2023 / Published: 3 February 2023 (This article belongs to the Special Issue Vasculitis) Download Download PDF Download PDF with Cover Download XML Download Supplementary Material Browse Figures Review Reports Versions Notes

Abstract: Immune checkpoint inhibitors (ICIs) have made an important contribution to the survival of patients with certain cancers. ICIs interrupt co-inhibitory signaling pathways mediated by programmed cell death protein 1 (PD-1), programmed cell death protein ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen (CTLA-4) that result in the elimination of cancer cells by stimulating the immune system. However, immune-related adverse events have also been described and attributed to an enhanced immune system activation. Recent observations have suggested a dysregulation of immune checkpoints in active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We here analyzed intrarenal PD-1 and PD-L1 by immunostaining in a total of 15 kidney biopsies with ANCA-associated renal vasculitis in correlation with glomerular and tubulointerstitial lesions. For independent validation, publicly available datasets were analyzed for PD-1 expression (encoded by PDCD1). We here observed a predominant tubulointerstitial expression of PD-1 that is decreased in ANCA-associated renal vasculitis. Moreover, loss of tubulointerstitial PD-1 correlated with active ANCA-associated renal vasculitis. Consistent with the observed association with active glomerular and tubulointerstitial lesions, we identified that interstitial PD-1 correlated with tubular and/or glomerular PD-L1 positivity. Finally, PD-1 was associated with decreased local synthesis of complement factor B. Interestingly, we did not observe a correlation between PD-1 and complement C5 or its C5a receptor. Combined with our observations, this may implicate a link between impaired PD-1/PD-L1 signaling, complement factor B and active ANCA-associated renal vasculitis. These findings could be of relevance because experimental data have already described that PD-1 agonism can be used therapeutically to attenuate autoimmunity in multiple disease models. Furthermore, targeted therapy against a complement C5/C5a receptor and factor B are both available and currently evolving in the treatment of AAV. Therefore, this pilot study expands our current knowledge and describes a potential interplay between immune checkpoints and the alternative complement pathway in active ANCA-associated renal vasculitis. Keywords: renal vasculitis; programmed cell death protein 1; complement factor B 1. IntroductionImmune checkpoint inhibitors (ICIs) have made an important contribution to the survival of patients with certain cancers. ICIs interrupt co-inhibitory signaling pathways mediated by programmed cell death protein 1 (PD-1), programmed cell death protein ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen (CTLA-4) that result in the elimination of cancer cells by stimulating the immune system. However, immune-related adverse events have also been described and attributed to an enhanced immune system activation. Recent observations have suggested a dysregulation of immune checkpoints in active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) [1]. This is in line with the fact that immune checkpoint molecules are present in injured kidneys independent of ICIs [2]. Regarding renal vasculitis, it was recently reported that specifically PD-1 inhibitors could cause de novo or relapsing ANCA-associated renal vasculitis [3]. These observations implicate the presence of the target molecule and a protective role of PD-1 signaling in renal vasculitis. AAV is a small vessel vasculitis, most frequently presenting as microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) [4,5]. Acute kidney injury (AKI) is a common and severe complication of AAV as it can cause progressive chronic kidney disease (CKD), end-stage renal disease (ESRD) or death [6,7]. Pathogenic ANCAs, in particular proteinase 3 (PR3) and myeloperoxidase (MPO), trigger a deleterious immune response resulting in pauci-immune necrotizing and crescentic renal vasculitis, a common manifestation of glomerular injury in AAV [8]. Seminal work has shown that complement depletion by cobra venom factor and blockade of the alternative complement pathway protected from experimental renal vasculitis [9]. Contrasting to this, complement C4 knockdown as a shared component of the classical and lectin pathway had no effect [9]. These findings first demonstrated that the alternative complement pathway is a prerequisite of ANCA-induced lesions. Interestingly, interstitial PD-1 has already been described as a determinant of susceptibility to kidney injury in the context of ICIs and has been linked to regulation by the complement system [10]. However, the presence of PD-1 and its association with the complement system in renal vasculitis have not been described yet. We hereby aimed to analyze the abundance of immune checkpoint molecules PD-1/PD-L1 and its implications in ANCA-associated renal vasculitis. 2. Results 2.1. Immune Checkpoints PD-1 and PD-L1 Are Present in Different Renal Compartments in ANCA-Associated Renal VasculitisWe first analyzed the abundance of PD-1 and PD-L1 among different intrarenal compartments in ANCA-associated renal vasculitis. In ANCA-associated renal vasculitis, immune checkpoint molecules PD-1 and PD-L1 were present (Figure 1A). While the presence of PD-1 was limited to interstitial cell positivity, PD-L1 was predominantly found in the tubular and glomerular compartment in ANCA-associated renal vasculitis (Figure 1B). In the case of PD-1 positivity, most were also positive for tubular and/or glomerular PD-L1 (Figure 1C). Interestingly, we did not observe tubular and/or glomerular PD-L1 positivity without the presence of PD-1 (Figure 1C). 2.2. Loss of Interstitial PD-1 Correlates with Active ANCA-Associated Renal VasculitisCorrelative analysis revealed that the loss of PD-1 associated with kidney injury in ANCA-associated renal vasculitis was attributed to active lesions including glomerular crescents (p = 0.0061) and necrosis (p = 0.0013), more tubulointerstitial inflammation including tubulitis (t, p = 0.0093), total inflammation (ti, p = 0.002) and inflammation in areas of interstitial fibrosis/tubular atrophy (i-IFTA, p = 0.0086, Figure 2A). This observation was further supported by subgrouping according to the Berden classification and ANCA renal risk score (ARRS); active ANCA-associated renal vasculitis correlated with the loss of interstitial PD-1 (Figure 2B,C). 2.3. PD-1 Associates with Decreased Local Synthesis of Complement Factor BFor independent validation, we next extracted mRNA levels of PDCD1 (encoding PD-1) from transcriptome array datasets. Here, we confirmed a predominant PDCD1 mRNA expression within the tubulointerstitial as compared to the glomerular compartment (p < 0.0001, Figure 3A). Interestingly, PDCD1 mRNA expression was significantly lower in ANCA-associated renal vasculitis as compared to healthy control kidneys (p = 0.0006, Figure 3B). Correlative analysis confirmed the association between loss of intrarenal PDCD1 mRNA expression and increased serum creatinine measurements (p = 0.0005, Figure 3C). Among complement system components, multivariate analysis revealed the strongest correlation between intrarenal mRNA levels of PDCD1 and decreased CFB (encoding complement factor B, p = 0.0001, Figure 3D). 3. DiscussionWe here observed a predominant tubulointerstitial expression of PD-1 that is decreased in ANCA-associated renal vasculitis. Moreover, the loss of tubulointerstitial PD-1 correlated with active ANCA-associated renal vasculitis. Consistent with the observed association with active glomerular and tubulointerstitial lesions, we identified that interstitial PD-1 correlated with tubular and/or glomerular PD-L1 positivity. Experimental studies have already described that disruption of the tissue-protective PD-1/PD-L1 checkpoint unleashes immunity in the pathogenesis of medium and large vessel vasculitites [11]. T-cell-dependent immune responses are modulated by costimulatory and coinhibitory stimuli, particularly receptor–ligand interactions that modulate T-cell receptor (TCR) signaling [12]. Such immune checkpoints are crucial for maintaining self-tolerance to prevent autoimmune disease and protect against tissue inflammation and damage [13]. Conversely, excessive expression of immune checkpoint proteins has been associated with immune resistance used by tumor cells to escape from antitumoral immunity [14]. Recent advances in cancer immunotherapy have highlighted the importance of PD-1/PD-L1 immune checkpoint blockade to suppress antigen-reactive TCR signaling with high efficacy in patients with advanced solid tumors [15,16,17]. PD-1 is expressed on activated T and B cells and its engagement by its ligand PD-L1 disrupts TCR activation and downstream signaling. Resulting immunosuppression involves several mechanisms, including T-cell apoptosis, T-cell exhaustion, T-cell anergy, IL-10 production and the induction of regulatory T cells [11]. In contrast with immune resistance, exacerbated immunity leads to immune-mediated tissue injury and autoimmune disease. PD-1 and PD-L1 deficiency have been associated with a lupus-like syndrome phenotype in mice [18]. Moreover, lack of PD-1 or PD-L1 accelerates experimental diabetes and autoimmune encephalitis [19,20]. On a mechanistic level, PD-L1 depletion in antigen-presenting cells results in a failure to convert naïve CD4+ into regulatory T cells (22) and PD-1 knockout mice are prone to enrich for Th1 and Th17 cells [21,22]. The fact that specifically PD-1 inhibitors can cause ANCA-associated renal vasculitis implicates a comparable mechanistic link between impaired immune checkpoint PD-1 signaling (by either targeted PD-1 therapy or loss of PD-1 itself) and disease activation [3]. Finally, PD-1 was associated with decreased local synthesis of complement factor B. A causal role of complement factor B has already been shown since its deficiency completely inhibited the development of renal vasculitis in mice [9]. Interestingly, we did not observe a correlation between PD-1 and complement C5 or its C5a receptor. Combined with our observations, this may imply a link between impaired PD-1/PD-L1 signaling, complement factor B and active ANCA-associated renal vasculitis. These findings could be of relevance because experimental data have already described that PD-1 agonism can be used therapeutically to attenuate autoimmunity in multiple disease models [23]. Furthermore, targeted therapy against both complement C5/C5a receptor and factor B is available and currently evolving in the treatment of AAV. Therefore, this pilot study expands our current knowledge and describes a potential interplay between immune checkpoints and the alternative complement pathway in active ANCA-associated renal vasculitis.Our study has several limitations, such as the small patient number and the retrospective study design. Furthermore, our observations are associative and do not prove causality, requiring mechanistic studies including protein levels of complement pathway components and in vitro culture models. Nevertheless, we hereby provide evidence for a potential interplay between immune checkpoints and the alternative complement pathway in active ANCA-associated renal vasculitis. Moreover, these findings might also be expandable and of interest for other inflammatory renal diseases. 4. Materials and Methods 4.1. Study Population and ApprovalA total of 15 kidney biopsies with ANCA-associated renal vasculitis at the University Medical Center Göttingen were included (Supplemental Table S1); part of the patient cohort has previously been described [24]. At the time of kidney biopsy, all patients received steroids, and further remission induction therapy was initiated thereafter based on histopathological confirmation of ANCA-associated renal vasculitis. Steroids were administered either as intravenous pulse therapy or orally with a tapering schedule. The use of parts of human specimens for research purposes was approved by the Ethics Committee of the University Medical Center Göttingen (protocol code: 28/09/17, approval date 17 November 2017). All patients gave written informed consent for the use of routinely collected data for research purposes as part of their regular medical care in the contract of the University Medical Center Göttingen, and all samples were deidentified. 4.2. Renal HistopathologyA kidney pathologist evaluated the kidney biopsies, and these were blinded to clinical data. Within a kidney biopsy, each glomerulus was scored separately for the presence of necrosis, crescents and global sclerosis. Based on these scorings, histopathological subgrouping according to Berden et al. was performed [25]. Furthermore, the ANCA renal risk score (ARRS) was evaluated according to Brix et al. [26]. Tubulointerstitial lesions were also evaluated analogously to the Banff scoring system for allograft pathology, as described previously [27]. Generally, Banff score lesions include interstitial inflammation (i), tubulitis (t), interstitial fibrosis (ci), tubular atrophy (ct), total inflammation (ti), inflammation in areas of IFTA (i-IFTA) and tubulitis in areas of IFTA (t-IFTA) [27]. The Banff scoring system had three grades: none (0), mild (1), moderate (2) and severe (3). The cut-off points for i were 50%, respectively. Cut-off points for t were 0, 1–4, 5–10 and >10 mononuclear cells/tubular cross section. Cut-off points for v were no arteritis, mild-to-moderate intimal arteritis in at least 1 arterial cross section, severe intimal arteritis with at least 25% luminal area lost in at least 1 arterial cross section, transmural arteritis and/or arterial fibrinoid change and medial smooth muscle necrosis with lymphocytic infiltration in vessel, respectively. Cut-off points for g were no glomerulitis, segmental or global glomerulitis in less than 25% of glomeruli, segmental or global glomerulitis in 25 to 75% of glomeruli and segmental or global glomerulitis in more than 75% of glomeruli. Cut-off points for ci were interstitial fibrosis in up to 5%, 6–25%, 26–50% and >50% of the cortical area. Cut-off points for ct were no tubular atrophy and tubular atrophy involving up to 25%, 26–50% and >50% of the area of cortical tubules. Cut-off points for ah were no PAS-positive hyaline arteriolar thickening, mild-to-moderate PAS-positive hyaline thickening in at least 1 arteriole, in more than 1 arteriole and in many arterioles. Cut-off points for ptc were a maximum number of leukocytes 10 leukocytes in most severely involved PTC. Cut-off points for ti were 50% of total cortical parenchyma inflamed. Cut-off points for i-IFTA and t-IFTA were no inflammation or less than 10%, 10–25%, 26–50% and >50% of scarred cortical parenchyma. 4.3. ImmunostainingImmunostainings were performed on 2 μm formalin-fixed, paraffin-embedded kidney sections. Kidney sections were deparaffinized in xylene and rehydrated in ethanol containing distilled water. Tissue sections were pre-treated using proteinase K antigen retrieval (DAKO, Glostrup, Denmark) and stained using primary antibodies against PD-1 (1:500, ab52587, Abcam, Cambridge, UK) and PD-L1 (1:100, ab205921, Abcam, Cambridge, UK); labeling was performed using NovolinkTM Polymer Detection System (Leica Biosystems, Wetzlar, Germany) according to the manufacturer’s protocol. Nuclear counterstain was performed by using Mayer’s hematoxylin solution (Sigma, St. Louis, MO, USA). As described previously, interstitial cells positive for PD-1 were evaluated using mean values of 10 randomly selected cortical visual fields at 400× magnification and scored semiquantitatively (0: no cell per visual field, 1: 1–3 cells per visual field, 2: 3–6 cells per visual field, 3: >6 cells per visual field) [10]. The intensity of PD-L1 staining was evaluated at 400× magnification and scored semiquantitatively (0: no staining, 1: weak and segmental staining, 2: moderate staining, 3: strong staining) [10]. 4.4. Analyses of Publicly Available Array DatasetsPublicly available datasets were analyzed for PD-1 expression (encoded by PDCD1) from Nephroseq (www.nephroseq.org, 30 September 2022, University of Michigan, Ann Arbor, MI). Particularly, median-centered log2 PDCD1 mRNA expression levels (reporter ID: 5133, platform: Affymetrix Human Genome U133 Plus 2.0 Array, altCDF v10) were extracted specifically from microdissected glomerular (21 with renal vasculitis, Supplemental Table S2) and tubulointerstitial compartments (31 healthy controls, 21 with renal vasculitis, Supplemental Table S3) [28]. In addition, tubulointerstitial mRNA expression of C1QA (reporter ID: 712), C1QB (713), C2 (717), C3 (718), C3AR1 (719), C5 (727), C5AR1 (728), CFB (629), CFD (1675), CFH (3075), CFP (5199), CR1 (1378) and CR2 (1380) were extracted (31 healthy controls, 21 with renal vasculitis) [28]. 4.5. Statistical MethodsVariables were tested for normal distribution using the Shapiro–Wilk test. Single-group comparison was performed using unpaired Student’s t test. Pearson’s (for normal distribution) and Spearman’s correlations (for non-normal distribution) were used to assess the univariate correlation between continuous variables. Multivariate analysis was performed by stepwise linear regression. Data analyses were performed with GraphPad Prism (version 9.3.1 for macOS, GraphPad Software, San Diego, CA, USA) and IBM SPSS Statistics (version 27 for MacOS, IBM Corporation, Armonk, NY, USA). A value of p < 0.05 was considered statistically significant. 5. ConclusionsWe hereby provide evidence for a potential interplay between immune checkpoints and the alternative complement pathway in active ANCA-associated renal vasculitis. These observations might contribute to a better understanding of pathomechanisms underlying complement system activation and dysregulation in ANCA-associated renal vasculitis. Supplementary MaterialsThe following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24032975/s1.Author ContributionsConceptualization, B.T.; methodology, B.T.; software, B.T.; validation, B.T.; formal analysis, S.H. and B.T.; investigation, S.H. and B.T.; resources, B.T.; data curation, S.H. and B.T.; writing—original draft preparation, B.T.; writing—review and editing, S.H.; visualization, B.T.; supervision, B.T.; project administration, B.T.; funding acquisition, B.T. All authors have read and agreed to the published version of the manuscript.FundingWe acknowledge support by the Open Access Publication Funds of the Göttingen University.Institutional Review Board StatementThe study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the University Medical Center Göttingen, Germany (protocol code: 28/09/17, approval date 17 November 2017).Informed Consent StatementPatient consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.Data Availability StatementThe original contributions presented in the study are included in the article/Supplementary Material; further data and material are available from the corresponding author upon reasonable request.Conflicts of InterestThe authors declare no conflict of interest.ReferencesGamerith, G.; Mildner, F.; Merkel, P.A.; Harris, K.; Cooney, L.; Lim, N.; Spiera, R.; Seo, P.; Langford, C.A.; Hoffman, G.S.; et al. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Ann. Rheum. Dis. 2022, 82, 253–261. [Google Scholar] [CrossRef] [PubMed]Hakroush, S.; Kopp, S.B.; Tampe, D.; Gersmann, A.-K.; Korsten, P.; Zeisberg, M.; Tampe, B. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition. Front. Immunol. 2021, 11, 624547. [Google Scholar] [CrossRef]Aqeel, F.; Monroy-Trujillo, J.; Geetha, D. Immune checkpoint inhibitors as potential triggers for ANCA vasculitis. RMD Open 2022, 8, e002500. [Google Scholar] [CrossRef] [PubMed]Jennette, J.C.; Falk, R.J.; Andrassy, K.; Bacon, P.A.; Churg, J.; Gross, W.L.; Hagen, E.C.; Hoffman, G.S.; Hunder, G.G.; Kallenberg, C.G.M.; et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994, 37, 187–192. [Google Scholar] [CrossRef] [PubMed]Jennette, J.C.; Falk, R.J.; Bacon, P.A.; Basu, N.; Cid, M.C.; Ferrario, F.; Flores-Suarez, L.F.; Gross, W.L.; Guillevin, L.; Hagen, E.C.; et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012, 65, 1–11. [Google Scholar] [CrossRef] [PubMed]Pettersson, E.E.; Sundelin, B.; Heigl, Z. Incidence and outcome of pauci-immune necrotizing and crescentic glomerulonephritis in adults. Clin. Nephrol. 1995, 43, 141–149. [Google Scholar] [PubMed]Hruskova, Z.; Stel, V.S.; Jayne, D.; Aasarød, K.; De Meester, J.; Ekstrand, A.; Eller, K.; Heaf, J.G.; Hoitsma, A.; Jimenéz, C.M.; et al. Characteristics and Outcomes of Granulomatosis with Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results from the European Renal Association–European Dialysis and Transplant Association Registry. Am. J. Kidney Dis. 2015, 66, 613–620. [Google Scholar] [CrossRef]Jennette, J.C.; Wilkman, A.S.; Falk, R.J. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am. J. Pathol. 1989, 135, 921–930. [Google Scholar]Xiao, H.; Schreiber, A.; Heeringa, P.; Falk, R.J.; Jennette, J.C. Alternative Complement Pathway in the Pathogenesis of Disease Mediated by Anti-Neutrophil Cytoplasmic Autoantibodies. Am. J. Pathol. 2007, 170, 52–64. [Google Scholar] [CrossRef]Tampe, D.; Kopp, S.B.; Baier, E.; Hakroush, S.; Tampe, B. Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity. Front. Med. 2022, 9, 902256. [Google Scholar] [CrossRef]Zhang, H.; Watanabe, R.; Berry, G.J.; Vaglio, A.; Liao, Y.J.; Warrington, K.J.; Goronzy, J.J.; Weyand, C.M. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc. Natl. Acad. Sci. USA 2017, 114, E970–E979. [Google Scholar] [CrossRef] [PubMed]Chen, L. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 2004, 4, 336–347. [Google Scholar] [CrossRef] [PubMed]Nishimura, H.; Honjo, T. PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001, 22, 265–268. [Google Scholar] [CrossRef] [PubMed]Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002, 99, 12293–12297. [Google Scholar] [CrossRef]Hamid, O.; Robert, C.; Daud, A.; Hodi, F.S.; Hwu, W.J.; Kefford, R.; Wolchok, J.D.; Hersey, P.; Joseph, R.W.; Weber, J.S.; et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369, 134–144. [Google Scholar] [CrossRef]Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 372, 2018–2028. [Google Scholar] [CrossRef]Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.M.; Hwu, W.-J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 2012, 366, 2455–2465. [Google Scholar] [CrossRef]Nishimura, H.; Nose, M.; Hiai, H.; Minato, N.; Honjo, T. Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor. Immunity 1999, 11, 141–151. [Google Scholar] [CrossRef]Keir, M.E.; Liang, S.C.; Guleria, I.; Latchman, Y.E.; Qipo, A.; Albacker, L.A.; Koulmanda, M.; Freeman, G.J.; Sayegh, M.H.; Sharpe, A.H. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 2006, 203, 883–895. [Google Scholar] [CrossRef]Latchman, Y.E.; Liang, S.C.; Wu, Y.; Chernova, T.; Sobel, R.A.; Klemm, M.; Kuchroo, V.K.; Freeman, G.J.; Sharpe, A.H. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 2004, 101, 10691–10696. [Google Scholar] [CrossRef]Francisco, L.M.; Salinas, V.H.; Brown, K.E.; Vanguri, V.K.; Freeman, G.J.; Kuchroo, V.K.; Sharpe, A.H. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206, 3015–3029. [Google Scholar] [CrossRef] [PubMed]McAlees, J.W.; Lajoie, S.; Dienger, K.; Sproles, A.A.; Richgels, P.K.; Yang, Y.; Khodoun, M.; Azuma, M.; Yagita, H.; Fulkerson, P.C.; et al. Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. Eur. J. Immunol. 2015, 45, 1019–1029. [Google Scholar] [CrossRef] [PubMed]Sugiura, D.; Okazaki, I.-M.; Maeda, T.K.; Maruhashi, T.; Shimizu, K.; Arakaki, R.; Takemoto, T.; Ishimaru, N.; Okazaki, T. PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity. Nat. Immunol. 2022, 23, 399–410. [Google Scholar] [CrossRef] [PubMed]Hakroush, S.; Tampe, D.; Korsten, P.; Ströbel, P.; Tampe, B. Complement Components C3 and C4 Indicate Vasculitis Manifestations to Distinct Renal Compartments in ANCA-Associated Glomerulonephritis. Int. J. Mol. Sci. 2021, 22, 6588. [Google Scholar] [CrossRef]Berden, A.E.; Ferrario, F.; Hagen, E.C.; Jayne, D.R.; Jennette, J.C.; Joh, K.; Neumann, I.; Noël, L.-H.; Pusey, C.D.; Waldherr, R.; et al. Histopathologic Classification of ANCA-Associated Glomerulonephritis. J. Am. Soc. Nephrol. 2010, 21, 1628–1636. [Google Scholar] [CrossRef]Brix, S.R.; Noriega, M.; Tennstedt, P.; Vettorazzi, E.; Busch, M.; Nitschke, M.; Jabs, W.J.; Özcan, F.; Wendt, R.; Hausberg, M.; et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018, 94, 1177–1188. [Google Scholar] [CrossRef]Roufosse, C.; Simmonds, N.; Groningen, M.C.-V.; Haas, M.; Henriksen, K.J.; Horsfield, C.; Loupy, A.; Mengel, M.; Perkowska-Ptasińska, A.; Rabant, M.; et al. A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology. Transplantation 2018, 102, 1795–1814. [Google Scholar] [CrossRef]Ju, W.; Nair, V.; Smith, S.; Zhu, L.; Shedden, K.; Song, P.X.K.; Mariani, L.H.; Eichinger, F.H.; Berthier, C.C.; Randolph, A.; et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci. Transl. Med. 2015, 7, 316ra193. [Google Scholar] [CrossRef] Ijms 24 02975 g001 550

Figure 1. Immune checkpoints PD-1 and PD-L1 are present in different renal compartments in ANCA-associated renal vasculitis. (A) Immunostainings for PD-1 (scale bar: 40 μm) and PD-L1 (scale bar: 100 μm) are shown; counterstaining was performed by using hematoxylin. Presence of PD-1 was limited to interstitial cell positivity (arrows); PD-L1 was found in the tubular, glomerular and vascular compartment in ANCA-associated renal vasculitis. (B) Quantification of PD-1 and PD-L1 is shown as fraction of total (n = 15). (C) Among cases with interstitial PD-1 (n = 10), frequency of tubular and glomerular PD-L1 positivity is shown. In case of PD-1 positivity, most were also positive for tubular and/or glomerular PD-L1. Figure 1. Immune checkpoints PD-1 and PD-L1 are present in different renal compartments in ANCA-associated renal vasculitis. (A) Immunostainings for PD-1 (scale bar: 40 μm) and PD-L1 (scale bar: 100 μm) are shown; counterstaining was performed by using hematoxylin. Presence of PD-1 was limited to interstitial cell positivity (arrows); PD-L1 was found in the tubular, glomerular and vascular compartment in ANCA-associated renal vasculitis. (B) Quantification of PD-1 and PD-L1 is shown as fraction of total (n = 15). (C) Among cases with interstitial PD-1 (n = 10), frequency of tubular and glomerular PD-L1 positivity is shown. In case of PD-1 positivity, most were also positive for tubular and/or glomerular PD-L1. Ijms 24 02975 g001

Figure 2. Loss of interstitial PD-1 correlates with active ANCA-associated renal vasculitis. (A) Correlations between PD-1 and PD-L1 positivity, markers of kidney injury and histopathological lesions in ANCA-associated renal vasculitis (n = 15) are shown by heatmap reflecting mean values of Spearman’s ρ; circle size represents significance level. (B,C) Quantification of interstitial PD-1 is shown as fraction of total according to Berden classification and ARRS. Figure 2. Loss of interstitial PD-1 correlates with active ANCA-associated renal vasculitis. (A) Correlations between PD-1 and PD-L1 positivity, markers of kidney injury and histopathological lesions in ANCA-associated renal vasculitis (n = 15) are shown by heatmap reflecting mean values of Spearman’s ρ; circle size represents significance level. (B,C) Quantification of interstitial PD-1 is shown as fraction of total according to Berden classification and ARRS. Ijms 24 02975 g002

Figure 3. PD-1 associates with decreased local synthesis of complement factor B. (A) Direct comparison between glomerular (n = 23) and tubulointerstitial median-centered log2 PDCD1 mRNA expression (n = 21) in renal vasculitis; comparison of groups was performed using unpaired t test (**** p < 0.0001). PDCD1 mRNA expression was predominantly found within the tubulointerstitial as compared to the glomerular compartment. (B) Direct comparison of tubulointerstitial median-centered log2 PDCD1 mRNA expression between healthy controls (n = 31) and renal vasculitis (n = 21); comparison of groups was performed using unpaired t test (*** p < 0.001). PDCD1 mRNA expression was significantly lower in ANCA-associated renal vasculitis as compared to healthy control kidneys. (C) Correlations between tubulointerstitial median-centered log2 PDCD1 mRNA expression and serum creatinine levels (n = 21) with Pearson’s r and significance level are shown. Loss of intrarenal PDCD1 mRNA expression correlated with increased serum creatinine measurements. (D) Correlations between tubulointerstitial median-centered log2 mRNA expression levels of PDCD1 and various complement components including healthy control kidneys (n = 31) and ANCA-associated renal vasculitis (n = 21) are shown by heatmap reflecting mean values of Pearson’s r. Circle size represents significance level in the univariate analysis, asterisk (*) in the multivariate analysis. PDCD1 mRNA expression associated with decreased expression levels of CFB. Figure 3. PD-1 associates with decreased local synthesis of complement factor B. (A) Direct comparison between glomerular (n = 23) and tubulointerstitial median-centered log2 PDCD1 mRNA expression (n = 21) in renal vasculitis; comparison of groups was performed using unpaired t test (**** p < 0.0001). PDCD1 mRNA expression was predominantly found within the tubulointerstitial as compared to the glomerular compartment. (B) Direct comparison of tubulointerstitial median-centered log2 PDCD1 mRNA expression between healthy controls (n = 31) and renal vasculitis (n = 21); comparison of groups was performed using unpaired t test (*** p < 0.001). PDCD1 mRNA expression was significantly lower in ANCA-associated renal vasculitis as compared to healthy control kidneys. (C) Correlations between tubulointerstitial median-centered log2 PDCD1 mRNA expression and serum creatinine levels (n = 21) with Pearson’s r and significance level are shown. Loss of intrarenal PDCD1 mRNA expression correlated with increased serum creatinine measurements. (D) Correlations between tubulointerstitial median-centered log2 mRNA expression levels of PDCD1 and various complement components including healthy control kidneys (n = 31) and ANCA-associated renal vasculitis (n = 21) are shown by heatmap reflecting mean values of Pearson’s r. Circle size represents significance level in the univariate analysis, asterisk (*) in the multivariate analysis. PDCD1 mRNA expression associated with decreased expression levels of CFB. Ijms 24 02975 g003

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Share and Cite MDPI and ACS Style

Hakroush, S.; Tampe, B. Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis. Int. J. Mol. Sci. 2023, 24, 2975. https://doi.org/10.3390/ijms24032975

AMA Style

Hakroush S, Tampe B. Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis. International Journal of Molecular Sciences. 2023; 24(3):2975. https://doi.org/10.3390/ijms24032975

Chicago/Turabian Style

Hakroush, Samy, and Björn Tampe. 2023. "Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis" International Journal of Molecular Sciences 24, no. 3: 2975. https://doi.org/10.3390/ijms24032975

Find Other Styles Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here. Article Metrics No No Article Access Statistics For more information on the journal statistics, click here. Multiple requests from the same IP address are counted as one view. Supplementary Material Supplementary File 1:

ZIP-Document (ZIP, 110 KiB)

AMA Style

Chicago/Turabian Style

Find Other Styles Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here. clear Int. J. Mol. Sci., EISSN 1422-0067, Published by MDPI RSS Content Alert Further Information Article Processing Charges Pay an Invoice Open Access Policy Contact MDPI Jobs at MDPI Guidelines For Authors For Reviewers For Editors For Librarians For Publishers For Societies For Conference Organizers MDPI Initiatives Sciforum MDPI Books Preprints Scilit SciProfiles Encyclopedia JAMS Proceedings Series Follow MDPI LinkedIn Facebook Twitter

© 1996-2023 MDPI (Basel, Switzerland) unless otherwise stated Disclaimer Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. Terms and Conditions Privacy Policy We use cookies on our website to ensure you get the best experience. Read more about our cookies here. Accept We have just recently launched a new version of our website. Help us to further improve by taking part in this short 5 minute survey here. here. Never show this again Share Link Copy clear Share https://www.mdpi.com/2112924 clear Back to TopTop

【本文地址】

公司简介

联系我们